NCT07478302RecruitingPhase 1
A Study of SHR-2524 Plus Bevacizumab in the First-line Treatment of Advanced Hepatocellular Carcinoma
To Investigate the Pharmacokinetics, Safety, Tolerability and Efficacy of SHR-2524 Combined With Bevacizumab in the First-line Treatment of Advanced Hepatocellular Carcinoma (HCC) in an Open-label, Multicenter Phase I Clinical Trial
Source: ClinicalTrials.gov · Last updated 1 May 2026
Brief summary (registry, in English)
This study was a multicenter, open-label phase I clinical trial. This trial will include 36 patients with advanced unresectable hepatocellular carcinoma. Blood samples were obtained during the course of treatment to measure the relative parameter. All Investigational Medicinal Products (IMP) were discontinued after the total cycle.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 36 (estimated)
- First submitted
- 12 Mar 2026
- Start date
- 14 Apr 2026
- Primary completion date
- Oct 2027
- Lead sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT07478302
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 36
- From 14 Apr 2026 to the primary completion date, Oct 2027
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous allogeneic organ transplantation (e.g., liver transplantation);
- CTCAE grade 3 bleeding had occurred within 6 months or CTCAE grade 2 nongastrointestinal bleeding had occurred within 3 months before the first dose;
- Abdominal fistula, gastrointestinal perforation, or abdominal abscess within 6 months before the first dose;
- Major vascular disease had occurred within 6 months before the first dose;
- Current concomitant interstitial pneumonia or interstitial lung disease, or a previous history of interstitial pneumonia or interstitial lung disease requiring hormone therapy;
- Severe infection occurred within 28 days before the first dose.
Other illness
- Patients with active malignant tumors other than HCC within 5 years or at the same time; Localized tumors that had been cured, such as skin basal cell carcinoma, skin squamous cell carcinoma, superficial bladder cancer, prostate cancer in situ, cervical cancer in situ, and breast cancer in situ, could be enrolled;
- Innate or acquired immune deficiency (such as HIV infection);
Other
- Hepatobiliary cell carcinoma, mixed hepatocellular carcinoma-cholangiocarcinoma, sarcomatoid hepatocellular carcinoma, and fibrolamellar hepatocellular carcinoma confirmed by histology or cytology;
- The current liver tumor burden is greater than 50% of the total liver volume;
Who the study is looking for
- ≥ 18 years old;
- Advanced hepatocellular carcinoma (HCC) confirmed by histopathology or cytology or clinical diagnosis;
- The Barcelona clinical liver cancer stage was B or C;
- Has not previously received systemic antitumor therapy for HCC;
- At least one measurable lesion according to RECIST v1.1 criteria;
- Child-Pugh score of A or B7 ;
- ECOG score 0 -1;
- The expected survival time was ≥12 weeks;
- The major organs functioned well;
- Has signed the informed consent form.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Mengchao Hepatobiliary Hospital of Fujian Medical University Coordinator of this site? Confirm its status | Fuzhou | China | Recruiting |
| The First Affiliated Hospital of Guangxi Medical University Coordinator of this site? Confirm its status | Nanning | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.